General Information of Drug (ID: DMR8W7Y)

Drug Name
AKCEA-ANGPTL3-LRX Drug Info
Indication
Disease Entry ICD 11 Status REF
Cardiovascular disease BA00-BE2Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMR8W7Y

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Evinacumab DMBLX7U Hypercholesterolaemia 5C80.0 Approved [2]
LNA043 DMDHVK8 Knee osteoarthritis FA01 Phase 2 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-related protein 3 (ANGPTL3) TTUO98L ANGL3_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
3 Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial. Nat Med. 2022 Dec;28(12):2633-2645.